Stocks making the biggest moves midday: Stanley Black & Decker, American Airlines, Dow, Marvell Technology & more

Midday trading was driven by multiple company-specific and geopolitical moves: Stanley Black & Decker rose more than 4% after saying recent Section 232 tariff changes should not materially affect full-year guidance, while Fermi fell more than 22% after its CFO resigned days after the CEO exit. Biogen gained nearly 3% on an $850 million China rights deal for felzartamab, and psychedelic stocks surged, with AtaiBeckley up more than 25% and Compass Pathways nearly 40%, after Trump ordered faster research and access. Airlines and cruise lines weakened on renewed U.S.-Iran tension and higher fuel-cost concerns, while TopBuild jumped more than 16% on QXO's $17 billion acquisition offer and QXO sank nearly 8%.

Analysis

The tape is being driven less by broad macro and more by idiosyncratic dispersion: policy relief, geopolitical supply risk, and governance shocks are overwhelming index-level signals. The cleanest takeaway is that balance-sheet quality and narrative credibility are being repriced faster than fundamentals, which tends to persist for days rather than hours when management credibility is involved, but only until the next data point on earnings or execution.

The most attractive second-order setup is in AI hardware and data-center infrastructure. If Marvell is indeed progressing on custom silicon with Google, the market will likely re-rate all foundry-adjacent names with customer-concentration risk, but Broadcom is the cleaner expression because its existing Google relationship makes the near-term cash-flow path more visible; Marvell’s pop looks more tactical than structural. By contrast, Fermi’s twin leadership departures are a red flag for project-finance credibility: names tied to power buildouts for AI should now trade on execution certainty, not just AI optionality, and that can spill into any pre-revenue infrastructure story that relies on repeated capital raises.

The M&A reaction in building products is interesting because the buyer is being punished more than the target is being rewarded. That usually means investors are questioning either financing cost, synergy timing, or integration complexity; in other words, the deal may be value-accretive on paper but dilutive to near-term multiple quality. In transportation, the market is still treating higher energy as a demand shock before it is a margin shock: airlines and cruise lines can see multiple compression quickly, while fertilizer and chemical names get a relative bid because supply-chain disruption and commodity linkage can offset weaker end-demand for a while.

The biotech/psychedelic rally is likely the most crowded and least durable move. The policy headline improves funding optionality, but it does not solve reimbursement, trial design, or commercialization timelines, so the right lens is call-option-like upside with a high probability of mean reversion. The better contrarian read is that the biggest winner may be the regulated, late-stage platforms that can absorb a policy tailwind without depending on speculative capital markets; those names are not the ones getting the biggest first-day move.

Key Decisions for Investors

• Long MRVL vs short AVGO for 1-3 weeks only if you want to fade the Google-chip headline into a more fully valued AI-ecosystem name; stop if MRVL closes below its pre-news level or if AVGO regains relative strength on volume.
• Avoid or short Fermi strength on any rebound for 1-4 weeks; the governance break reduces financing credibility and raises the probability of follow-on dilution or project delays, making rallies sellable rather than buyable.
• Buy AAL/UAL downside via short-dated puts into any energy-driven bounce in crude; this is a 2-6 week trade with asymmetric payoff if oil stays elevated and consumer confidence weakens further.
• Pair long CF or DOW against short NCLH or a basket of airlines for a geopolitical-duration trade over the next few sessions; the setup favors upstream commodity-linked exposure over demand-sensitive travel if shipping risk remains elevated.
• Fade CMPS/ATAI strength with small size via call spreads or outright shorts after the initial policy squeeze; the move is likely to decay as the market refocuses on regulatory, reimbursement, and execution risk over the next 1-3 months.